Abstract: Described herein is a gene construct comprising a nucleotide sequence encoding insulin, for use in the treatment and/or prevention of neuroinflammation, neurodegeneration and/or cognitive decline, or a disease or condition associated therewith.

Abstract: The invention relates to protein particles comprising a cluster of one or more types of assembled self-contained protein, wherein the particle has a size from 50 nm to 50 micrometers; is in form of a pellet in aqueous media; is mechanically stable; and it release a particular percentage by weight of the self-contained protein within a predetermined period of time, and any other compound contained in the particle. Particular methods for obtaining the particles are also disclosed, said methods comprising the addition of salts to allow precipitation of proteins. Particular protein particles comprising lipids associated with the assembly of self-contained proteins are also disclosed. The invention also relates to several uses of the particle, in particular medical uses and to pharmaceutical and cosmetic compositions comprising the particles.

Abstract: The present invention provides new adeno-associated virus-derived vectors and pharmaceutical compositions containing the same for the treatment of lysosomal storage disorders and specially, for the treatment of mucopolysaccharidoses Type IIID.

Abstract: The present invention relates to a chipless RFID tag (T), comprising: —a dielectric substrate (1); and —electromagnetic resonators (3) excitable by an external electromagnetic field and respectively arranged on separate spatial locations of the dielectric substrate (1) forming a row, and configured to resonate at a common resonant frequency. The dielectric substrate (1) defines several predetermined encoding areas that include the separate spatial locations, so that data is encoded by the presence/absence of operative electromagnetic resonators (3) thereon. The present invention also relates to a system comprising the chipless RFID tag of the invention and a RFID reader (R) reading an encoded code by detecting the presence/absence of attenuation peaks on an electromagnetic wave providing the external electromagnetic field to the electromagnetic resonators (3). The present invention also relates to a method for encoding data on a chipless RFID tag defined according to the present invention.

Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with myocardial infarction.

Abstract: Described herein is a gene construct comprising a nucleotide sequence encoding a fibroblast growth factor 21 (FGF21), for use in the treatment and/or prevention of a metabolic disorder, wherein the therapy involves expression of the gene construct in the central nervous system (CNS).

Abstract: The present invention provides new adenoassociated virus vectors and pharmaceutical compositions containing the same for the treatment of lysosomal storage disorders and specially, for the treatment of mucopolysaccharidoses Type IIIB.

Abstract: An apparatus and a method using no switching elements for multiplexing and reading arrays of sensors whose electrical resistance is modulated by the signals to be measured are proposed. Sensor elements are arranged in groups and columns where each column is fed with a continuous voltage waveform of different amplitude, frequency and phase characteristics which then produce current signals that are modulated by the variable resistance signals to be measured. Modulated currents are summed row-wise and collected at the read-out circuits, either by applying a constant voltage to each row of the array or by connecting a capacitor and converting these current summations into output voltage signals. The read-out circuits de-multiplex each individual sensor signal to be measured by lock-in demodulation according to the frequencies and phases employed for the stimulation of each column.

Abstract: The invention relates to a specific panel of circulating synaptic protein related miRNAs for use in the diagnosis of Mild Cognitive Impairment (MCI) and/or early diagnosis of Alzheimer's disease (AD). The invention also relates to a method and to a kit for the diagnosis of said diseases using said specific panel of circulating miRNAs biomarkers.

Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.

Abstract: A method (100) and a system for determining pH values of fermented/acidified animal/vegetable milk products from inline optical measurements, the method comprising: emitting light into a fermented/acidified animal/vegetable milk product (101); optically detecting scattering light coming from said fermented/acidified animal/vegetable milk product, generated from said emitted light once received therein, to collect scattered light data (102); calculating by a computing device including one or more processors running an algorithm at least one value of a variable from the collected scattered light data (103); and obtaining, by said computing device a pH value of the fermented/acidified animal/vegetable milk product by using said at least one calculated value of a variable (104), wherein a single wavelength is used for collecting the scattered light data.

Abstract: The invention relates to a viral expression construct and related viral vector and composition and to their use wherein the construct and vector comprise elements a) and b): a) a nucleotide sequence encoding an insulin operably linked to a first promoter, b) a nucleotide sequence encoding a glucokinase operably linked to a second promoter and the viral expression construct and related viral vector comprise at least one of elements c), d) and e): c) the first and the second promoters are positioned in reverse orientation within the expression construct, d) the first and the second promoters are positioned in reverse orientation within the expression construct and are located adjacent to each other and e) the first promoter is a CMV promoter, preferably a mini CMV promoter.

Abstract: The invention relates to methods for predicting the clinical outcome of cancer patients, and in particular of acute lymphoblastic leukaemia (ALL) patients, in response to a therapy against ALL, preferably conventional chemotherapy, more preferably based on glucocorticoids, said methods based on the presence of particular polymorphism in genes coding for drug-metabolizing enzymes and apoptotic proteins. The invention relates as well to method for predicting the efficacy of a therapy based on conventional glucocorticoids as well as to method for personalized medicine in patients carrying said polymorphisms.

Abstract: New gene therapy constructions and compositions are the subject of present invention. The gene therapy compositions consist in adeno-associated vectors which jointly express insulin (Ins) and glucokinase (Gck) genes. The new gene therapy constructions are useful for treatment of diabetes either in dogs or human beings.

Abstract: The present invention relates to a chipless RFID tag (T), comprising: —a dielectric substrate (1); and —electromagnetic resonators (3) excitable by an external electromagnetic field and respectively arranged on separate spatial locations of the dielectric substrate (1) forming a row, and configured to resonate at a common resonant frequency. The dielectric substrate (1) defines several predetermined encoding areas that include the separate spatial locations, so that data is encoded by the presence/absence of operative electromagnetic resonators (3) thereon. The present invention also relates to a system comprising the chipless RFID tag of the invention and a RFID reader (R) reading an encoded code by detecting the presence/absence of attenuation peaks on an electromagnetic wave providing the external electromagnetic field to the electromagnetic resonators (3). The present invention also relates to a method for encoding data on a chipless RFID tag defined according to the present invention.

Abstract: The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors. The invention also relates to pharmaceutical compositions comprising said vectors.

Abstract: Conjugates comprising a targeting moiety specific for the CXCR4 and based on the polyphemusin-derived peptide and a therapeutic or imaging agent are provided. Therapeutic and diagnostic methods with the conjugates which require specific targeting to CXCR4+ cells are provided as well.

Abstract: The present invention relates to a process for removing the fouling deposited in a milk processor unit after a thermal processing of milk or a food product including milk at a T between 80° C. and 150° C. for at least 4 hours, including said fouling proteins, lactose, minerals and products formed therefrom, comprising the step of applying a cleaning solution on said fouling deposited in the milk processor unit. The present invention further relates to a cleaning solution for removing the fouling deposited in a milk processor unit.

Abstract: The present invention relates to adeno-associated viral vector useful for transducing adipose tissue. The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vector. The invention also relates to gene therapy methods useful for the treatment of a disease that requires the regulation of the expression levels of a gene.

Abstract: The present invention relates to adeno-associated viral vector useful for transducing adipose tissue. The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vector. The invention also relates to gene therapy methods useful for the treatment of a disease that requires the regulation of the expression levels of a gene.